FDA Clears ReAlta Life Science’s Phase II STAR Trial of RLS-0071 in Neonates with Hypoxic-Ischemic Encephalopathy

ReAlta Life Sciences, Inc. announced FDA clearance of an investigational new drug application for a Phase II clinical trial of RLS-0071 in neonates with hypoxic-ischemic encephalopathy.